MedPath

Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate

Phase 2
Completed
Conditions
Acute Kidney Failure
Registration Number
NCT00472563
Lead Sponsor
Universidad de Antioquia
Brief Summary

Deterioration of kidney renal function occurs in a minority of people due to contrast-required procedures. The purpose of this study is to compare two different interventions to reduce the risk of kidney injury after contrast medium exposition.

We will perform a randomized clinical trial following a modification of a previously published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.

Detailed Description

We will perform a randomized clinical trial following a modification of a previously published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.

Phase 2/3 study Study Type: Interventional Study Design: Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study.

Subjects: Consecutive samples of all inpatients who meet the inclusion criteria

Primary outcomes: Development of contrast induced nephropathy, defined as an increase in serum creatinine of 25% or more within 48 h after administration of contrast.

Secondary outcomes: change in serum bicarbonate; change in serum potassium; change in serum creatinine.

Expected total enrollment: 212

Allocation Assignment: Patients who meet inclusion criteria and agree to participate in the study will be assigned by a random number table to saline or bicarbonate, using closed envelopes and stratifying according to history of diabetes and type of procedure (cardiac catheterism or others).

Condition: Contrast Induced Nephropathy

Intervention: 75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W

Gender: both Age: 18+ years of age Recruitment Status: participants are currently being recruited

Facility location:

Universidad de Antioquia, Internal Medicine Department; Hospital Universitario San Vicente de Paul. Medellin, Colombia.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
212
Inclusion Criteria
  • 18+ years of age

  • Inpatient at Hospital Universitario San Vicente de Paúl scheduled to undergo diagnostic CT scan using contrast or angiography and either

    • Serum creatinine 1.2 mg/dl or more, or
    • Type 2 Diabetes Mellitus
Exclusion Criteria
  • Current clinical diagnosis of exacerbated congestive heart failure
  • Exposure to contrast 30 days prior to study
  • Allergy to contrast dye
  • Chronic renal disease with dialysis therapy
  • Acute renal failure with dialytic urgency
  • Urgency procedure needed
  • Systolic blood pressure < 90 or vasopressor support
  • No authorization by patient or physician in charge
  • Serum potassium < 3 mEq/L
  • Ejection fraction < 35% by previous echocardiography
  • Acute pulmonary edema in previous 48 hours

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
development of contrast induced nephropathy, defined as an increase in serum creatinine of 25% or more within 48 h after administration of contrast48 h
Secondary Outcome Measures
NameTimeMethod
change in serum bicarbonate; change in serum potassium; change in serum creatinine48 h

Trial Locations

Locations (1)

Hospital Universitario San Vicente Paúl

🇨🇴

Medellín, Antioquia, Colombia

© Copyright 2025. All Rights Reserved by MedPath